Funding for this research was provided by:
Vetenskapsrådet (2018-02532, 2017-00915)
Swedish State Support for Clinical Research (ALFGBG-720931)
Swedish Stare Support for Clinical Research (ALFGBG-715986)
European Research Council (681712)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Swedish Alzheimer Foundation (AF-742881)
Received: 13 July 2020
Accepted: 10 December 2020
First Online: 22 December 2020
Ethics approval and consent to participate
: The study was approved by the Ethics Committee of Paris Diderot University Hospital (Bichat Hospital). All patients or caregivers gave their written informed consents for research, which was conducted in accordance with the Helsinki Declaration. The use of de-identified leftover samples for method development and validation studies was approved by the Regional Ethical Review Board at University of Gothenburg (08-11-14).
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors declare that they have no competing interests.